RRR-α-tocopherol succinate down-regulates oncogenic Ras signaling

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 309-316

  Donapaty, Sreenivasa ^a   Louis, Somaja ^b   Horvath, Elizabeth ^a   Kun, Jiang ^a   Sebti, Said M ^a   Malafa, Mokenge P ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHEROL SUCCINATE; BIOLOGICAL MARKER; CYCLIN D1; H RAS PROTEIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; ATTENUATION; CANCER CELL CULTURE; CANCER MODEL; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRAIN HCT116; CELL SURVIVAL; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVITY; FIBROBLAST CULTURE; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; E2F TRANSCRIPTION FACTORS; HUMANS; MICE; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); VITAMIN E;

EID: 33644968607     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0330     Document Type: Article

References (54)

1. Neuzil J. Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity. Br J Cancer 2003;89:1822-6.
2. Kline K, Yu W, Sanders BG. Vitamin E and breast cancer. J Nutr 2004;134:3458-62S.
3. Prasad KN, Kumar B, Yan XD, Hanson AJ, Cole WC. α-Tocopheryl succinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr 2003;22:108-17.
4. Weber T, Lu M, Andera L, et al. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clin Cancer Res 2002;8:863-9.
5. Tomasetti M, Gellert N, Procopio A, Neuzil J. A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: a future drug against a fatal neoplastic disease? Int J Cancer 2004;109:641-2.
6. Stapelberg M, Gellert N, Swettenham E, et al. α-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: mechanism and the role of oxidative stress. J Biol Chem 2005;280:25369-76.
7. Malafa MP, Neitzel LT. Vitamin E succinate promotes breast cancer tumor dormancy. J Surg Res 2000;93:163-70.
8. Israel K, Sanders BG, Kline K. RRR-α-Tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr Cancer 1995;24:161-9.
9. Turley JM, Funakoshi S, Ruscetti FW, et al. Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: role for transforming growth factor β. Cell Growth Differ 1995;6:655-63.
10. Simmons-Menchaca M, Qian M, Yu W, Sanders BG, Kline K. RRR-α-Tocopheryl succinate inhibits DNA synthesis and enhances the production and secretion of biologically active transforming growth factor-β by avian retrovirus-transformed lymphoid cells. Nutr Cancer 1995;24:171-85.
11. Yu W, Sanders BG, Kline K. RRR-α-Tocopheryl succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. Nutr Cancer 1997;27:92-101.
12. Zhang M, Altuwaijri S, Yeh S. RRR-α-Tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004;23:3080-8.
13. Malafa MP, Fokum FD, Smith L, Louis A. Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate. Ann Surg Oncol 2002;9:1023-32.
14. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000;36:90-100.
15. Yamamoto S, Tamai H, Ishisaka R, et al. Mechanism of α-tocopheryl succinate-induced apoptosis of promyelocytic leukemia cells. Free Radic Res 2000;33:407-18.
16. Neuzil J, Tomasetti M, Mellick AS, et al. Vitamin E analogues: a new class of inducers of apoptosis with selective anti-cancer effects. Curr Cancer Drug Targets 2004;4:355-72.
17. Neuzil J, Weber T, Schroder A, et al. Induction of cancer cell apoptosis by α-tocopheryl succinate: molecular pathways and structural requirements. Faseb J 2001;15:403-15.
18. Neuzil J, Weber T, Gellert N, Weber C. Selective cancer cell killing by α-tocopheryl succinate. Br J Cancer 2001;84:87-9.
19. You H, Yu W, Sanders BG, Kline K. RRR-α-Tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ 2001;12:471-80.
20. Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, Kline K. Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E succinate and vitamin E analogue, α-TEA. Cancer Res 2004;64:4263-9.
21. Shun MC, Yu W, Gapor A, et al. Pro-apoptotic mechanisms of action of a novel vitamin E analog (α-TEA) and a naturally occurring form of vitamin E (δ-tocotrienol) in MDA-MB-435 human breast cancer cells. Nutr Cancer 2004;48:95-105.
22. Yu W, Liao QY, Hantash FM, Sanders BG, Kline K. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-α-tocopheryl succinate-induced apoptosis of human breast cancer cells. Cancer Res 2001;61:6569-76.
23. Charpentier A, Simmons-Menchaca M, et al. RRR-α-Tocopheryl succinate enhances TGF-β1, -β2, and -β3 and TGF-βR-II expression by human MDA-MB-435 breast cancer cells. Nutr Cancer 1996;26: 237-50.
24. Yu W, Heim K, Qian M, Simmons-Menchaca M, Sanders BG, Kline K. Evidence for role of transforming growth factor-β in RRR-α-tocopheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells. Nutr Cancer 1997;27:267-78.
25. Bang OS, Park JH, Kang SS. Activation of PKC but not of ERK is required for vitamin E-succinate-induced apoptosis of HL-60 cells. Biochem Biophys Res Commun 2001;288:789-97.
26. You H, Yu W, Munoz-Medellin D, Brown PH, Sanders BG, Kline K. Role of extracellular signal-regulated kinase pathway in RRR-α-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Mol Carcinog 2002;33:228-36.
27. Yu W, Sanders BG, Kline K. RRR-α-Tocopheryl succinate induction of DNA synthesis arrest of human MDA-MB-435 cells involves TGF-β-independent activation of p21Waf1/Cip1. Nutr Cancer 2002;43:227-36.
28. Prasad KN, Kumar A, Kochupillai V, Cole WC. High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr 1999;18:13-25.
29. Turley JM, Ruscetti FW, Kim SJ, Fu T, Gou FV, Birchenall-Roberts MC. Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: increased binding of cyclin A negatively regulates E2F transactivation activity. Cancer Res 1997;57:2668-75.
30. Stapelberg M, Tomasetti M, Alleva R, Gellert N, Procopio A, Neuzil J. α-Tocopheryl succinate inhibits proliferation of mesothelioma cells by selective down-regulation of fibroblast growth factor receptors. Biochem Biophys Res Commun 2004;318:636-41.
31. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette DC III, Birchenall-Roberts MC. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res 1997;57:881-90.
32. Yu W, Israel K, Liao QY, Aldaz CM, Sanders BG, Kline K. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res 1999;59: 953-61.
33. Wu K, Li Y, Zhao Y, et al. Roles of Fas signaling pathway in vitamin E succinate-induced apoptosis in human gastric cancer SGC-7901 cells. World J Gastroenterol 2002;8:982-6.
34. Qian M, Kralova J, Yu W, et al. c-Jun involvement in vitamin E succinate induced apoptosis of reticuloendotheliosis virus transformed avian lymphoid cells. Oncogene 1997;15:223-30.
35. Zhao B, Yu W, Qian M, et al. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol Carcinog 1997;19:180-90.
36. Yu W, Simmons-Menchaca M, You H, et al. RRR-α-Tocopheryl succinate induction of prolonged activation of c-Jun amino-terminal kinase and c-Jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog 1998;22:247-57.
37. Weber T, Dalen H, Andera L, et al. Mitochondria play a central role in apoptosis induced by α-tocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. Biochemistry 2003;42:4277-91.
38. Neuzil J, Svensson I, Weber T, Weber C, Brunk UT. α-Tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation. FEBS Lett 1999;445:295-300.
39. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-603.
40. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-87.
41. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003;4:111-20.
42. Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998;16: 1467-73.
43. Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr Top Med Chem 2002;2:303-23.
44. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8: 83-96.
45. Buday L, Downward J. Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993;73:611-20.
46. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
47. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol 2000;10:147-54.
48. Wittinghofer A. Signal transduction via Ras. Biol Chem 1998;379: 933-7.
49. Simpson L, Parsons R. PTEN: life as a tumor suppressor. Exp Cell Res 2001;264:29-41.
50. Gilhooly EM, Rose DP. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 1999;15:267-70.
51. Klampfer L, Huang J, Corner G, et al. Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem 2003;278:46278-87.
52. Prasad KN, Cohrs RJ, Sharma OK. Decreased expressions of c-myc and H-ras oncogenes in vitamin E succinate induced morphologically differentiated murine B-16 melanoma cells in culture. Biochem Cell Biol 1990;68:1250-5.
53. Cohrs RJ, Torelli S, Prasad KN, Edwards-Prasad J, Sharma OK. Effect of vitamin E succinate and a cAMP-stimulating agent on the expression of c-myc and N-myc and H-ras in murine neuroblastoma cells. Int J Dev Neurosci 1991;9:187-94.
54. Yano Y, Satoh H, Fukumoto K, et al. Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-α-tocotrienol, a redox-silent derivative of α-tocotrienol. Int J Cancer 2005;115: 839-46.